Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -22.19 | — | — | — | 10.51 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 8.13 | 23.29 | 7.93 | 26.90 | 22.13 | 7.21 | — | 39.08 | 19.14 | 22.09 | 10.49 | 18.91 | 10.63 |
| — | +222.9% | — | -31.2% | +15.6% | -67.4% | — | +106.7% | +80.0% | -22.2% | -43.6% | -34.1% | -68.2% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | 2.15 | 2.68 | 1.24 |
| — | — | — | — | — | — | — | — | — | — | -18.3% | +16.4% | -76.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 9.63 | — | 5.98 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Armata Pharmaceuticals, Inc.'s operating margin was -670.9% in Q3 2025, down 355.4 pp QoQ and down 342.8 pp YoY. The trailing four-quarter average of -877.0% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 23.9% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -565.4% | 68.1% | 83.1% | 23.2% | 69.2% | 89.5% | — | 67.2% | 80.8% | 82.0% | 79.6% | -1106.5% | -810.5% |
| — | -23.9% | — | -65.4% | -14.3% | +9.2% | — | +106.1% | +110.0% | +115.5% | +121.0% | -101.4% | -109.6% | |
| Operating Margin | -820.2% | -670.9% | -315.5% | -1668.2% | -853.4% | -328.2% | — | -1058.8% | -626.9% | -843.8% | -982.6% | -1425.4% | -982.7% |
| — | -104.5% | — | -57.6% | -36.1% | +61.1% | — | +25.7% | +36.2% | -30.9% | -100.7% | -100.8% | -60.7% | |
| Net Margin | -365.6% | -2301.6% | -751.3% | -1330.1% | 210.5% | -184.4% | — | -2590.2% | -1298.9% | -2543.8% | -361.9% | -1820.4% | -981.4% |
| — | -1148.4% | — | +48.6% | +116.2% | +92.8% | — | -42.3% | -32.4% | -295.1% | +26.0% | -156.4% | -60.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | -922.3% | -17.1% | -49.5% | -25.3% |
| — | — | — | — | — | — | — | — | — | -5193.1% | -6.3% | -145.3% | -2.7% | |
| ROA | -20.5% | -31.3% | -19.4% | -7.5% | 2.8% | -5.3% | 7.9% | -22.9% | -18.8% | -29.1% | -3.4% | -14.2% | -10.9% |
| — | -490.3% | -346.8% | +67.1% | +115.0% | +81.8% | +332.7% | -61.5% | -72.0% | -227.8% | +61.7% | -43.3% | -1.6% | |
| ROIC | -44.2% | -8.5% | -7.4% | -8.9% | -11.2% | -10.0% | -12.1% | -10.3% | -9.4% | -10.2% | -9.7% | -11.8% | -11.9% |
| — | +15.4% | +39.3% | +14.2% | -18.3% | +1.4% | -25.8% | +12.0% | +20.9% | +9.6% | +24.1% | +4.7% | -1.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 36.1% YoY to 0.12x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 3.57 | 3.45 | 1.35 |
| — | — | — | — | — | — | — | — | — | — | +388.4% | +451.5% | -9.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.23 | 0.12 | 0.06 | 0.12 | 0.23 | 0.19 | 0.25 | 0.38 | 1.16 | 1.67 | 0.52 | 0.75 | 1.09 |
| — | -36.1% | -75.0% | -68.6% | -79.9% | -88.7% | -51.8% | -49.5% | +7.0% | -64.8% | -90.7% | -90.4% | -65.1% | |
| Quick Ratio | 0.23 | 0.12 | 0.06 | 0.12 | 0.23 | 0.19 | 0.25 | 0.39 | 1.16 | 1.67 | 0.52 | 0.75 | 1.09 |
| — | -36.1% | -75.0% | -69.8% | -79.9% | -88.7% | -51.8% | -47.4% | +7.0% | -64.8% | -90.7% | -90.4% | -65.1% | |
| Interest Coverage | -3.95 | -1.79 | -1.80 | -2.27 | -3.21 | -3.34 | -4.38 | -5.62 | -6.61 | -8.79 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArmata Pharmaceuticals, Inc.'s current P/E is -22.2x. The average P/E over the last 1 quarters is 10.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Armata Pharmaceuticals, Inc.'s current operating margin is -820.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Armata Pharmaceuticals, Inc.'s business trajectory between earnings reports.